Yu Hao

Mrs. Yu Hao

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
HLHui Liu
Hui Liu
LYLeiming You
Leiming You
JWJun Wu
Jun Wu
MZMengfan Zhao
Mengfan Zhao
RGRui Guo
Rui Guo
YHYu Hao
Yu Hao

10 June 2011 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
YWYing Wu
Ying Wu
JLJi-Qian Li
Ji-Qian Li
YKYe-Ji Kim
Ye-Ji Kim
JWJun Wu
Jun Wu
QWQian Wang
Qian Wang
YHYu Hao
Yu Hao

21 October 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LSLei Shi
Lei Shi
XHXiao Han
Xiao Han
JLJun-Xiang Li
Jun-Xiang Li
YLYu-Ting Liao
Yu-Ting Liao
FKFu-Shun Kou
Fu-Shun Kou
YHYu Hao
Yu Hao
Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses


16 September 2022 in Drug Development Research
Verified
Journal Article
Closed access
CAChen An
Chen An
YWYanmin Wu
Yanmin Wu
JWJun Wu
Jun Wu
HLHuanwei Liu
Huanwei Liu
SZSiyao Zhou
Siyao Zhou
YHYu Hao
Yu Hao

1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RGRui Guo
Rui Guo
MZMengfan Zhao
Mengfan Zhao
HLHui Liu
Hui Liu
RSRina Su
Rina Su
QMQin Mao
Qin Mao
YHYu Hao
Yu Hao
Xijiao Dihuang decoction combined with Yinqiao powder (XDD-YQP) is a classical combination formula; however, its therapeutic effects in treating influenza viral pneumonia and the pharmacological mechanisms remain unclear. The therapeutic effect of XDD-YQP in influenza viral pneumonia was evaluated in mice. Subsequently, an everted gut sac model coupled with UPLC/Q-TOF MS were used to screen and identify the active compounds of XDD-YQP. Furthermore, network pharmacological analysis was adopted to probe the mechanisms of the active compounds. Lastly, we verified the targets predicted from network pharmacological analysis by differential bioinformatics analysis. Animal experiments showed that XDD-YQP has a therapeutic effect on influenza viral pneumonia. Moreover, 113 active compounds were identified from intestinal absorbed solutions of XDD-YQP. Using network pharmacological analysis, 90 major targets were selected as critical in the treatment of influenza viral pneumonia through 12 relevant pathways. Importantly, the MAPK signaling pathway was found to be closely associated with the other 11 pathways. Moreover, seven key targets, EGFR, FOS, MAPK1, MAP2K1, HRAS, NRAS, and RELA, which are common targets in the MAPK signaling pathway, were investigated. These seven key targets were identified as differentially expressed genes (DEGs) between influenza virus-infected and uninfected individuals. Hence, the seven key targets in the MAPK signaling pathway may play a vital role in the treatment of influenza viral pneumonia with XDD-YQP. This research may offer an integrative pharmacology strategy to clarify the pharmacological mechanisms of traditional Chinese medicines. The results provide a theoretical basis for a broader clinical application of XDD-YQP.